Advancing Treatment of Disease with Innovative protein therapeutics and Technologies

Advancing therapeutics against hepatitis C

Diseases caused by chronic viral infections such as hepatitis C virus (HCV) are a growing public health problem. Up to 170 million people worldwide have chronic HCV infection1, including 3.2 million people in the US2. Chronic HCV infection is a major risk factor for developing liver cancer and is a leading cause for liver transplants1. While effective treatments are available for treating chronic HCV infection, only 5 in 10 patients achieve a sustained response1. That leaves a substantial number of patients with an unmet need for effective treatment of HCV.

The standard therapy for chronic HCV infection is a combination of two drugs: interferon-alpha (IFN-α) and ribavirin (RBV)3. Newer drugs on the market including protease inhibitors such as telaprevir and boceprevir, as well as other drugs in development can be added to boost response rates, but they do not overcome the main limitations of chronic HCV treatment including the severe side effects associated with chronic RBV usage.

Therapure Innovations has applied its novel Protein Drug Conjugation technology as a means to potentially improve the safety and efficacy of RBV treatment. This platform technology takes advantage of hemoglobin, a natural protein the body uses to transport oxygen to tissues. The body keeps a steady supply of this important protein by producing it in the bone marrow and metabolizing it in the liver. By linking RBV to hemoglobin, the drug can be delivered to the liver to improve the drug’s efficacy while reducing systemic toxicity, providing a direct benefit to patients.


  1. Centers for Disease Control and Prevention. Chapter 3 Infectious Diseases Related To Travel. Available here . Accessed Aug 14, 2013.
  2. Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals. Available here . Accessed Aug 14, 2013.
  3. Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine 2013;2(9):1-8.

To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at